Susquehanna Fundamental Investments’s PDL BioPharma, Inc. PDLI Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-77,000	Closed	-$226K	–	542
2018 Q1	$226K	Buy	+77,000	New	+$210K	0.03%	396

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna Fundamental Investments's PDLI Position: Q2 2018 in Review

Susquehanna Fundamental Investments sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 77,000 shares — an estimated $226K sold.

Susquehanna Fundamental Investments first reported a position in PDLI in Q1 2018 and held it in 1 quarter. The position peaked at $226K in Q1 2018. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Susquehanna Fundamental Investments reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Susquehanna Fundamental Investments sold 77,000 PDL BioPharma, Inc. shares in Q2 2018, an estimated $226K.
Susquehanna Fundamental Investments first reported a position in PDL BioPharma, Inc. in Q1 2018 and held it in 1 quarter.
Susquehanna Fundamental Investments's PDL BioPharma, Inc. position peaked at $226K in Q1 2018.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2018, filed 14 Aug 2018.